Drugs / IM-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04121169 | Oct 2019 → Dec 2023 | Clostridium difficile colitis | ImmuniMed Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04121169 ↗ |
| Action | Inhibit | “Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile” NCT04121169 ↗ |
| Modality | Protein / enzyme biologic | “IM-01 egg-derived anti-C. difficile polyclonal antibodies” NCT04121169 ↗ |
| Route | Oral | “Upon reconstitution, IM-01 is administered orally” NCT04121169 ↗ |